(Ombitasvir + paritaprevir + ritonavir) + dasabuvir is a Small Molecule owned by AbbVie, and is involved in 38 clinical trials, of which 36 were completed, and 2 are ongoing.

Ombitasvir is an inhibitor of HCV NS5A, which is essential for viral RNA replication and virion assembly. Paritaprevir is an inhibitor of the HCV NS3/4A protease which is necessary for the proteolytic cleavage of the HCV encoded polyprotein (into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins) and is essential for viral replication. Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase encoded by the NS5B gene, which is essential for replication of the viral genome. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of paritaprevir and overall drug exposure.

The revenue for (Ombitasvir + paritaprevir + ritonavir) + dasabuvir is expected to reach a total of $29m through 2028. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Ombitasvir + paritaprevir + ritonavir) + dasabuvir NPV Report.

(Ombitasvir + paritaprevir + ritonavir) + dasabuvir is currently owned by AbbVie.

(Ombitasvir + paritaprevir + ritonavir) + dasabuvir Overview

Paritaprevir, ritonavir, ombitasvir is a antiviral fixed dose combination preparation, co-packed with dasabuvir (Viekira Pak, Viekirax + Exviera, Holkira Pak) acts as anti-hepatitis C preparation. It is formulated as film-coated tablets for the oral route of administration. Viekira Pak with or without ribavirin is indicated for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis. Viekira Pak without ribavirin is indicated in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection and compensated cirrhosis (Child-Pugh A). Viekira Pak is also indicated for genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.

The drug candidate is under development for the treatment of hepatitis C virus infection in pediatric patients.

AbbVie Overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.

The company reported revenues of (US Dollars) US$56,197 million for the fiscal year ended December 2021 (FY2021), an increase of 22.7% over FY2020. In FY2021, the company’s operating margin was 31.9%, compared to an operating margin of 24.8% in FY2020. In FY2021, the company recorded a net margin of 20.5%, compared to a net margin of 10.1% in FY2020. The company reported revenues of US$14,812 million for the third quarter ended September 2022, an increase of 1.6% over the previous quarter.

Quick View – (Ombitasvir + paritaprevir + ritonavir) + dasabuvir

Report Segments
  • Innovator (NME)
Drug Name
  • (Ombitasvir + paritaprevir + ritonavir) + dasabuvir
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.